Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
GLP-1 receptor agon
>>
Phase 2
Welcome,
Profile
Billing
Logout
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
3
6
9
12
15
18
21
24
27
30
cotadutide
(MEDI0382) / AstraZeneca
danuglipron immediate release
(PF-06882961 IR) / Pfizer
efinopegdutide
(HM12525A) / Merck (MSD)
lotiglipron
(PF-07081532) / Pfizer
noiiglutide
(SHR20004) / Jiangsu Hengrui Pharma
HRS-7535
/ Jiangsu Hengrui Pharma
pemvidutide
(ALT-801) / Altimmune
bamadutide
(SAR425899) / Sanofi
GZR18
/ Gan & Lee Pharma
HR17031
/ Jiangsu Hengrui Pharma
NN9541
/ Novo Nordisk
RG6641
/ Roche
RG7697
/ Roche
albenatide
(CJC-1134-PC) / ConjuChem, Changshan Kaijiejian Biopharma
dapiglutide
(ZP7570) / Zealand Pharma
froniglutide
(PF1801) / ImmunoForge
maridebart cafraglutide
(AMG 133) / Amgen
semaglutide SC once-daily
/ Novo Nordisk
HS-20094
/ Jiangsu Hansoh Pharma
MK-8521
/ Merck (MSD)
amycretin oral
(NN9487 oral) / Novo Nordisk
efocipegtrutide
(HM15211) / Hanmi
pegapamodutide
(OPK88003) / OPKO Health
DD01
/ D&D Pharmatech
PB-718
/ PegBio
RGT-075
/ Regor
exenatide SR two week formulation
(PT302) / Peptron
pegylated exenatide
(NLY01-PD) / D&D Pharmatech
vurolenatide
(NM-002) / 9 Meters Biopharma
TTP054
/ vTv Therapeutics
TTP273
/ vTv Therapeutics
exenatide SR two-week formulation
(PT320) / Peptron
exenatide once monthly suspension
/ BMS
pegylated form of exenatide for diabetes
(NLY01-D) / D&D Pharmatech
utreglutide
(GL0034) / Sun Pharma
